Showing results (21-30 of 159) with videos related to
Sort By:
Pageof 16
Bulletin Du Cancer|March 19, 2023
Evolution of parenteral nutrition practices in a comprehensive cancer center: Comparative auditsAlexandre Peinoit, Léa Muzellec, Mickael Som, et al.Journal of Vascular and Interventional Radiology : JVIR|November 25, 2015
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line ViabilityJulien Edeline, Cédric Coulouarn, Laurence Crouzet, et al.Cancers|March 10, 2022
Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion PaperJean-Luc Raoul, Julien Edeline, Victor Simmet, et al.Cancer Treatment Reviews|May 22, 2018
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyondJean-Luc Raoul, Masatoshi Kudo, Richard S Finn, et al.The European Journal of General Practice|January 5, 2021
Adverse events of targeted therapies reported by patients with cancer treated in primary careSamuel Roger, Julien Edeline, Boris Campillo-Gimenez, et al.Current Oncology (Toronto, Ont.)|September 27, 2023
Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular CarcinomaVictoria Foy, Mairéad G McNamara, Juan W Valle, et al.Expert Opinion on Investigational Drugs|August 23, 2021
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trialsHéloïse Bourien, Angela Lamarca, Mairéad G McNamara, et al.Fundamental & Clinical Pharmacology|March 17, 2025
Second primary cancers and hormonal therapies for prostate cancer: A nested case-control studyLucie-Marie Scailteux, Julien Bezin, Marion Gundelwein, et al.Surgery|February 24, 2015
Extended liver resections for intrahepatic cholangiocarcinoma: friend or foe?Damien Bergeat, Laurent Sulpice, Michel Rayar, et al.European Journal of Cancer (Oxford, England : 1990)|February 28, 2012
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimenJulien Edeline, Yohann Loriot, Stephane Culine, et al.Pageof 16